Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
NewsAnticipates having product available to ship in January 2024
NEW YORK— November 2, 2023—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of…
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
NewsCourse to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis
NEW YORK— October 30, 2023—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company…
Eyenovia To Present Data On Preservative-Free Microbial Integrity Of The Optejet®
NewsIn rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions.
Presentation to be made at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual…
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
News
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the…
Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals
News
APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery
Further leverages Eyenovia’s Mydcombi sales force and represents additional…
Eyenovia Announces First Commercial Sale of MydCombi™
News
Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation
Validates Eyenovia’s proprietary Optejet® dispensing platform
World-renowned board-certified ophthalmologist…
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
News
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing…
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
NewsRepresents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis
Provides critical validation of key technology that is core to Eyenovia’s proprietary development programs as well as current and future…
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
NewsAnnounced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023
Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining…
Eyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement
News
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs…
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
NewsCollaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant…
Eyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops
NewsAcademic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company…
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
NewsAgency assigns PDUFA action date of May 8, 2023
MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel Optejet® drug delivery technology
Company also announced receipt of California Medical Device Manufacturing…
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
NewsTransaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi™
NEW YORK, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial…
Eyenovia announces positive results from VISION-2 Phase 3 Study of MicroLine as a potential on-demand treatment for presbyopia
News
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs…
Recent Posts
- Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update November 13, 2023
- Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production November 3, 2023
- Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program October 30, 2023
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com